GH Guardant Health, Inc.

Nasdaq guardanthealth.com


$ 97.80 $ -0.21 (-0.21 %)    

Tuesday, 11-Nov-2025 16:47:02 EST
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 97.71
$ 96.78
$ 96.00 x 418
$ 99.60 x 1
$ 96.75 - $ 99.31
$ 28.45 - $ 101.57
1,900,647
na
12.32B
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-29-2025 09-30-2025 10-Q
2 07-30-2025 06-30-2025 10-Q
3 04-30-2025 03-31-2025 10-Q
4 02-20-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-02-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-10-2019 03-31-2019 10-Q
28 03-19-2019 12-31-2018 10-K
29 11-19-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guardant-health-expands-guardant-reveal-blood-test-to-monitor-late-stage-cancer-therapy-response

New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early dise...

 guardant-health-data-from-shield-blood-based-screening-test-shows-95-patient-adherence-for-colorectal-cancer

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Curr...

 guardant-health-announces-proposed-300m-offering-of-convertible-senior-notes-due-2033

Guardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced its intent...

 guardant-health-announces-250m-underwritten-public-offering-of-its-common-stock

Guardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced the commen...

 teradyne-wayfair-and-illumina-are-among-the-top-10-large-cap-gainers-last-week-oct-27-oct-31-are-the-others-in-your-portfolio

Top weekly large-cap gainers included Teradyne, Wayfair, Illumina, Guardant Health, ASE, C.H. Robinson, Lumen, Symbotic, Credo,...

 ubs-maintains-buy-on-guardant-health-raises-price-target-to-110

UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $80 to $110.

 citigroup-maintains-buy-on-guardant-health-raises-price-target-to-100

Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $65 to ...

 evercore-isi-group-maintains-outperform-on-guardant-health-raises-price-target-to-90

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price tar...

 barclays-maintains-overweight-on-guardant-health-raises-price-target-to-85

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $70 t...

 canaccord-genuity-maintains-buy-on-guardant-health-raises-price-target-to-100

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $75 ...

 btig-maintains-buy-on-guardant-health-raises-price-target-to-100

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $80 to $100.

 correction-guardant-health-q3-adj-eps-039-beats-077-estimate-sales-265196m-beat-235692m-estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.77)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION